Unity Biotechnology

New Publication in Nature Medicine Supports Therapeutic Potential of Senolytics to Provide Long-lasting, Disease-modifying Intervention in Vision Loss

Retrieved on: 
Tuesday, February 6, 2024
Biotechnology, Paper, SAN, Cell, Research, VEGF, Therapy, Ageing, Environment, Patient, Diabetic retinopathy, Hyperglycemia, Unity Biotechnology, Retina, Homeostasis, Visual acuity, UBX, Cellular senescence, Diabetes, Endothelium, DME, University, Eye, Metalloproteinase, Nature Medicine, Université de Montréal, Pharmaceutical industry

Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.

Key Points: 
  • Sustained hyperglycemia from diabetes induces cellular senescence which damages the retina, including the delicate vasculature in the eye.
  • This can lead to fluid accumulation and retinal thickening – a key feature of DME.
  • They demonstrated that these senescent cells contribute to loss of barrier function, which can cause leaky blood vessels.
  • This research further supports the potential for senolytic medicines to address the significant unmet need with current standard of care.”

UNITY Biotechnology Doses First Patients in Phase 2 ASPIRE Study of UBX1325 in DME

Retrieved on: 
Tuesday, December 12, 2023
Biotechnology, Unity Biotechnology, DME, Diabetic retinopathy, SAN, Standard of care, CST, Ageing, Patient, UBX, Safety, Therapy, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema (DME).

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Dec. 12, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced that the first patients have been dosed in the Phase 2 ASPIRE study of UBX1325 (foselutoclax), a Bcl-xL inhibitor being evaluated head-to-head against standard of care anti-VEGF in patients with diabetic macular edema (DME).
  • “Many patients with DME have poor vision despite frequent anti-VEGF injections and there is an urgent need to develop new treatment options for such patients,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
  • “There has been great interest from the physician community in the therapeutic potential of UBX1325, which is based on a novel senolytic mechanism of action, and we are excited to have dosed our first patients in the ASPIRE study.
  • Secondary endpoints will include change in BCVA over time, and central subfield thickness (CST) change from baseline to week 24.

UNITY Biotechnology, Inc. Reports Third Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Monday, November 13, 2023
Research, Safety, SAN, Visual acuity, Diabetic retinopathy, Depreciation, Patient, DME, Biotechnology, Therapy, UBX, Ageing, AMD, Operating cost, Unity Biotechnology, Pharmaceutical industry, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the third quarter ended September 30, 2023.
  • It is expected to enroll about 40 subjects, with 16-week data expected in the fourth quarter of 2024 and 24-week data expected in the first quarter of 2025.
  • Operating loss for the three months ended September 30, 2023 was $15.3 million compared to $13.7 million for the three months ended September 30, 2022.
  • Cash used in operations during the nine quarters of 2023 was $29.5 million compared to $40.7 million for the nine quarters of 2022.

UNITY Biotechnology Announces Exercise of Warrants for $4.38 Million in Gross Proceeds

Retrieved on: 
Friday, November 10, 2023
Sale, SAN, Security (finance), Form, Exercise, Peer-to-peer file sharing, Clinical trial, Biotechnology, Therapy, UBX, Ageing, Unity Biotechnology

The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No.

Key Points: 
  • The shares of common stock issuable upon exercise of the warrants are registered pursuant to an effective registration statement on Form S-3 (File No.
  • The gross proceeds to UNITY from the exercise of the warrants are expected to be approximately $4.38 million, prior to deducting placement agent fees and offering expenses.
  • In consideration for the immediate exercise of the warrants for cash, UNITY will issue new unregistered warrants to purchase up to 2,143,000 shares of common stock.
  • UNITY has agreed to file a registration statement with the SEC covering the resale of the shares of common stock issuable upon exercise of the new warrants.

UNITY Biotechnology Announces 48-Week Results from Phase 2 ENVISION Study of UBX1325 in Patients with Wet Age-Related Macular Degeneration

Retrieved on: 
Wednesday, September 27, 2023
UNITY, Colic flexures, Biotechnology, Therapy, Anti-VEGF, DME, AMD, Ageing, Diabetic retinopathy, Part, Inflammation, Unity Biotechnology, Patient, Endophthalmitis, UBX, Visual acuity, Safety, Disease, Birth control, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Sept. 27, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced results from Part B of the Phase 2 ENVISION study of UBX1325 in patients with wet age-related macular degeneration (AMD) who were not achieving optimum benefit with their ongoing anti-VEGF therapy.

Key Points: 
  • Patients switched from every 8-week aflibercept to a combination of aflibercept and UBX1325 at week 24 maintained vision gains achieved with aflibercept alone through week 48.
  • “The ENVISION study shows that patients with wet AMD who switch from anti-VEGF to UBX1325 can maintain visual acuity with a significant reduction in anti-VEGF treatment burden.
  • Patients with more severe disease may benefit from a combination of aflibercept and UBX1325,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
  • UNITY has initiated a Phase 2b study in patients with diabetic macular edema and expects to randomize the first patient in that study in Q4 2023.

Arcutis Appoints Interim Chief Financial Officer (CFO)

Retrieved on: 
Friday, August 18, 2023
IPO, Biotechnology, Unity, Allergan, Dermatitis, Unity Biotechnology, Psoriasis, Gilead, Dermatology, CFO, Growth, Kite Pharma, Therapy, Skin, Management, Pharmaceutical industry

WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that John W. Smither, who served as Arcutis’ first Chief Financial Officer (CFO) from 2019 to 2021, has been appointed interim CFO effective August 31.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Aug. 18, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced that John W. Smither, who served as Arcutis’ first Chief Financial Officer (CFO) from 2019 to 2021, has been appointed interim CFO effective August 31.
  • “We are delighted that John has agreed to step in as interim CFO.
  • He brings an incredible depth and breadth of both financial acumen and dermatology experience from his 25+-year career in the pharmaceutical industry, culminating in five successive CFO roles including his previous stint at Arcutis,” said Frank Watanabe, President and Chief Executive Officer of Arcutis.
  • “On behalf of our Board and team, I would like to thank Scott for his tremendous contributions to Arcutis.

UNITY Biotechnology, Inc. Reports Second Quarter 2023 Financial Results and Business Updates

Retrieved on: 
Tuesday, August 8, 2023
UNITY, Biotechnology, Therapy, DME, AMD, Ageing, Diabetic retinopathy, Part, Unity Biotechnology, Patient, SAN, UBX, Depreciation, Research, Pharmaceutical industry, Cryptocurrency

SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023.

Key Points: 
  • SOUTH SAN FRANCISCO, Calif., Aug. 08, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the second quarter ended June 30, 2023.
  • Also in the third quarter, the Company expects to activate clinical trial sites in ASPIRE with the first patient dosed shortly thereafter.
  • UNITY believes that current cash, cash equivalents and marketable securities are sufficient to fund operations into the fourth quarter of 2024.
  • Cash used in operations during the first and second quarters of 2023 was $22.4 million compared to $29.8 million for the first and second quarters of 2022.

Annexon Biosciences Strengthens Leadership Team with Appointment of Jamie Dananberg, M.D., as Chief Medical Officer

Retrieved on: 
Thursday, July 27, 2023
Tufts University, UNITY, Endocrinology, Biotechnology, Drug development, University, Takeda, Eli Lilly and Company, Head, Unity Biotechnology, Science, Eli Lilly, Lilly, Patient, Collection, Metabolism, Takeda Pharmaceutical Company, Pharmaceutical industry

BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief medical officer.

Key Points: 
  • BRISBANE, Calif., July 27, 2023 (GLOBE NEWSWIRE) -- Annexon, Inc. (“Annexon”) (Nasdaq: ANNX), a clinical-stage biopharmaceutical company developing a new class of complement-based medicines for patients with classical complement-mediated autoimmune, neurodegenerative and ophthalmic disorders, today announced the appointment of Jamie Dananberg, M.D., as chief medical officer.
  • “We are delighted to join forces with Jamie during this exciting time for Annexon.
  • Most recently, he served as the chief medical officer for UNITY Biotechnology, where as one of its earliest employees, he built the medical and broader development organization.
  • Before joining Lilly, he practiced medicine in endocrinology and metabolism and ran a basic science laboratory at the University of Michigan.

UNITY Announces Design of Phase 2b ASPIRE Study Evaluating UBX1325 in Diabetic Macular Edema (DME)

Retrieved on: 
Wednesday, June 21, 2023
Retina, UNITY, Biotechnology, Therapy, DME, Ageing, Unity Biotechnology, Patient, Standard of care, CST, UBX, Visual acuity, Safety, Pharmaceutical industry, Surveying

SOUTH SAN FRANCISCO, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [Nasdaq: UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today announced the design of its Phase 2b ASPIRE clinical trial, which will evaluate UBX1325 (foselutoclax) head-to-head against aflibercept in previously treated patients with active diabetic macular edema (DME) who are not achieving optimal benefit from standard of care. UNITY expects to begin activating clinical trial sites in the third quarter and dose the first patient in the fourth quarter of 2023.

Key Points: 
  • UNITY expects to begin activating clinical trial sites in the third quarter and dose the first patient in the fourth quarter of 2023.
  • “The Phase 2b ASPIRE Study is designed to provide a clear and robust comparison between UBX1325 and the standard of care aflibercept in a head-to head trial in patients with DME,” said Anirvan Ghosh, Ph.D., chief executive officer of UNITY.
  • “Participants in the study drug arm will receive three doses of UBX1325 over the duration of the study, in a frequency that mirrors the real-world dosing schedule in the aflibercept arm.
  • UNITY will begin activating clinical trial sites in the ASPIRE study in Q3 2023 and expects the first patient to be dosed in Q4 2023.

Stonegate Healthcare Partners Announces Publishing of a Thematic Report - Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease

Retrieved on: 
Thursday, June 1, 2023
DME, SHP, DR, OCS, Diabetic retinopathy, Unity Biotechnology, VEGF, Pharmaceutical industry, Telescopic sight, Pecten oculi

Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME).

Key Points: 
  • Dallas, Texas--(Newsfile Corp. - June 1, 2023) - Stonegate Healthcare Partners (SHP), a healthcare strategy consulting firm, is pleased to announce the release of a thematic report that examines innovative advancements in the treatment of diabetic eye disease, including diabetic retinopathy (DR) and diabetic macular edema (DME).
  • The report, Beyond VEGF: Therapies Revolutionizing Diabetic Eye Disease, highlights the unmet needs and the companies leading innovation in this field.
  • This thematic report will serve as the foundation for Stonegate Healthcare's ongoing market intelligence in diabetic eye disease, providing valuable insights for investors and companies.
  • Based on interviews and analysis with dozens of companies and KOLs, this report offers an important resource for anyone seeking an understanding of diabetic eye disease treatment.